九哥的个人主页 - 老虎社区

九哥

暂无个人介绍

IP属地：北京

86关注

1粉丝

7主题

0勋章

2025-06-12

在美股中上市的稀土相关股票，以及各自的市场竞争优势

股价暴涨788%！抗衰老基因疗法研长寿命20%

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"49788700068555","uuid":"49788700068555","gmtCreate":1452115362056,"gmtModify":1457535214214,"name":"九哥","pinyin":"jgjiuge","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","hatId":"ca_profile_frame_Lm11L6","hatName":"","vip":1,"status":2,"fanSize":1,"headSize":86,"tweetSize":1,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":7,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":45,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-3","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识航海家","description":"观看学堂课程满50节","bigImgUrl":"https://static.tigerbbs.com/21acbb5884e07b96522d8d84c4b7acea","smallImgUrl":"https://static.tigerbbs.com/e4e8dc2edfbfee912f4e68fe6c23b3f0","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.08%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":7,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":445091186847848,"gmtCreate":1749686371755,"gmtModify":1749691844357,"author":{"id":"49788700068555","authorId":"49788700068555","name":"九哥","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"49788700068555","idStr":"49788700068555"},"themes":[],"htmlText":"在美股中上市的稀土相关股票，以及各自的市场竞争优势","listText":"在美股中上市的稀土相关股票，以及各自的市场竞争优势","text":"在美股中上市的稀土相关股票，以及各自的市场竞争优势","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/445091186847848","repostId":"2542320144","repostType":2,"repost":{"id":"2542320144","kind":"news","pubTimestamp":1749608427,"share":"https://www.laohu8.com/m/news/2542320144?lang=zh_CN&edition=full","pubTime":"2025-06-11 10:20","market":"us","language":"zh","title":"股价暴涨788%！抗衰老基因疗法研长寿命20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542320144","media":"生物药大时代","summary":"受此利好推动，该公司股价在美股市场随即暴涨787.8%，成交量突破10亿股。Kuro-O的实验室随后发表了首个证据，证明小鼠体内基因过度表达全长Klotho基因，使小鼠的寿命比正常小鼠寿命延长了30%-40%。使用AAV9载体将表达s-KL的基因注射到小鼠体内，可有效提高血清中s-KL的浓度，使小鼠寿命延长20%。","content":"<html><body><article><p>声明：因水平有限，错误不可避免，或有些<a href=\"https://laohu8.com/S/300469\">信息</a>非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。</p><p>2025年6月9日，美国<a href=\"https://laohu8.com/S/000504\">生物</a>遗传学公司<a href=\"https://laohu8.com/S/KLTO\">Klotho Neurosciences</a>（KLTO）宣布了积极的临床前数据，通过AAV9载体递送分泌型Klotho蛋白（s-KL）可有效增加小鼠血清中s-KL的浓度，使其寿命延长20%。此外，提高Klotho基因表达可以同时减少多个器官与年龄相关的退化，延长寿命和健康寿命，促进健康老龄化。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20250611102116827v2017x3hep9ay0d\"/><p>受此利好推动，该公司股价在美股市场随即暴涨787.8%，成交量突破10亿股。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20250611102132614v2018rin7omxyjs\"/><p>Klotho蛋白由KL基因编码，其表达水平与寿命及整体健康状况密切相关，目前作为一种重要的<a href=\"https://laohu8.com/S/600201\">生物</a>分子在衰老研究领域受到了广泛关注。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20250611102135626v2018btewpi8j37\"/><p>Makoto Kuro-O教授在1997年的开创性发现表明，血液中的Klotho浓度与哺乳动物的寿命直接相关——Klotho血液水平越低，寿命越短。Kuro-O的实验室随后发表了首个证据，证明小鼠体内基因过度表达全长Klotho基因，使小鼠的寿命比正常小鼠寿命延长了30%-40%。从那时起，Klotho蛋白因其能够影响与新陈代谢、炎症和组织修复相关的关键生物途径而受到广泛关注，这些途径与衰老过程密切相关。</p><p>Joan Roig-Soriano及其同事领导的一系列实验发表在2025年2月版的《Molecular Therapy》上，凸显了天然分泌型Klotho蛋白（“s-KL”）的潜力及其对健康衰老小鼠和具有快速衰老表型的小鼠的影响。使用AAV9载体将表达s-KL的基因注射到小鼠体内，可有效提高血清中s-KL的浓度，使小鼠寿命延长20%。这篇最近发表的论文进一步证明了KLTO开发s-KL作为减少与年龄相关的退化的治疗方法的可行性。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20250611102139437v201d778ocujyfb\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250611102140520v201qojswo8if0k\"/><p>值得注意的是，关键观察结果显示，尽管衰老是许多疾病的主要风险因素，包括认知能力下降、神经炎症、肌肉减少症和骨质疏松症，但分泌型蛋白s-KL因其涉及与细胞损伤、应激和炎症相关的多条通路的多种生物学效应——这表明这种单一治疗方法可能同时解决衰老的多方面影响。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20250611102141155v201j12qnqannf1\"/><p>从战略角度来看，KLTO 已获得了强大的知识产权地位。KLTO已从巴塞罗那自治大学 (UAB) 和西班牙加泰罗尼亚高等研究院（ICREA）获得了s-KL的全球独家许可。并且，公司拥有美国、欧洲和中国颁发的专利，这些专利涵盖哺乳动物Klotho的分泌剪接变体s-KL，用于治疗神经退行性疾病和与年龄相关的疾病。</p><p>Klotho Neurosciences核心技术在于，通过专利化的可分泌型 α-Klotho(s-KL) 基因递送载体，开发一次性或低频给药的体内基因疗法。产品管线主要包括：针对ALS、MS等其他神经肌肉疾病的KLTO-202（预计2025 Q4提交IND）；针对阿尔茨海默病、帕金森病和亨廷顿氏病的KLTO-101(临床前)，以及针对动脉硬化、急性肾病、慢性肾脏病的KLTO-301(临床前)。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20250611102149490v2013dew1tvzugj\"/><p>KLTO专注于神经退行性疾病，包括肌萎缩侧索硬化症 (ALS)、阿尔茨海默病和帕金森病，这些疾病代表着巨大的市场机遇和大量未满足的需求。虽然这些结果仍处于临床前阶段，但其针对衰老基本过程而非仅仅针对症状的机制方法展现了其科学的复杂性。多器官获益表明，其应用范围不仅局限于神经退行性疾病，还可能扩展到更广泛的抗衰老治疗领域——这是一个快速增长的细分市场。</p><p>参考资料：</p><p>[1]https://www.prnewswire.com/news-releases/klotho-neuroscience-inc-announces-an-approach-to-increase-longevity-and-healthy-life-span--replace-a-silenced-gene-called-alpha-klotho--klotho-302476036.html</p><p>[2]Roig-Soriano J, Edo Á, Verdés S, et al. Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience. Mol Ther. 2025;33(4):1449-1465. doi:10.1016/j.ymthe.2025.02.030</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>股价暴涨788%！抗衰老基因疗法研长寿命20%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n股价暴涨788%！抗衰老基因疗法研长寿命20%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-11 10:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611102211a702ef83&s=b><strong>生物药大时代</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。2025年6月9日，美国生物遗传学公司Klotho Neurosciences（KLTO）宣布了积极的临床前数据，通过AAV9载体递送分泌型Klotho蛋白（s-KL）可有效增加小鼠血清中s-KL的浓度，使其寿命延长20%。此外，提高Klotho基因表达...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611102211a702ef83&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KLTO":"Klotho Neurosciences, Inc.","BK4139":"生物科技"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611102211a702ef83&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2542320144","content_text":"声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。2025年6月9日，美国生物遗传学公司Klotho Neurosciences（KLTO）宣布了积极的临床前数据，通过AAV9载体递送分泌型Klotho蛋白（s-KL）可有效增加小鼠血清中s-KL的浓度，使其寿命延长20%。此外，提高Klotho基因表达可以同时减少多个器官与年龄相关的退化，延长寿命和健康寿命，促进健康老龄化。受此利好推动，该公司股价在美股市场随即暴涨787.8%，成交量突破10亿股。Klotho蛋白由KL基因编码，其表达水平与寿命及整体健康状况密切相关，目前作为一种重要的生物分子在衰老研究领域受到了广泛关注。Makoto Kuro-O教授在1997年的开创性发现表明，血液中的Klotho浓度与哺乳动物的寿命直接相关——Klotho血液水平越低，寿命越短。Kuro-O的实验室随后发表了首个证据，证明小鼠体内基因过度表达全长Klotho基因，使小鼠的寿命比正常小鼠寿命延长了30%-40%。从那时起，Klotho蛋白因其能够影响与新陈代谢、炎症和组织修复相关的关键生物途径而受到广泛关注，这些途径与衰老过程密切相关。Joan Roig-Soriano及其同事领导的一系列实验发表在2025年2月版的《Molecular Therapy》上，凸显了天然分泌型Klotho蛋白（“s-KL”）的潜力及其对健康衰老小鼠和具有快速衰老表型的小鼠的影响。使用AAV9载体将表达s-KL的基因注射到小鼠体内，可有效提高血清中s-KL的浓度，使小鼠寿命延长20%。这篇最近发表的论文进一步证明了KLTO开发s-KL作为减少与年龄相关的退化的治疗方法的可行性。值得注意的是，关键观察结果显示，尽管衰老是许多疾病的主要风险因素，包括认知能力下降、神经炎症、肌肉减少症和骨质疏松症，但分泌型蛋白s-KL因其涉及与细胞损伤、应激和炎症相关的多条通路的多种生物学效应——这表明这种单一治疗方法可能同时解决衰老的多方面影响。从战略角度来看，KLTO 已获得了强大的知识产权地位。KLTO已从巴塞罗那自治大学 (UAB) 和西班牙加泰罗尼亚高等研究院（ICREA）获得了s-KL的全球独家许可。并且，公司拥有美国、欧洲和中国颁发的专利，这些专利涵盖哺乳动物Klotho的分泌剪接变体s-KL，用于治疗神经退行性疾病和与年龄相关的疾病。Klotho Neurosciences核心技术在于，通过专利化的可分泌型 α-Klotho(s-KL) 基因递送载体，开发一次性或低频给药的体内基因疗法。产品管线主要包括：针对ALS、MS等其他神经肌肉疾病的KLTO-202（预计2025 Q4提交IND）；针对阿尔茨海默病、帕金森病和亨廷顿氏病的KLTO-101(临床前)，以及针对动脉硬化、急性肾病、慢性肾脏病的KLTO-301(临床前)。KLTO专注于神经退行性疾病，包括肌萎缩侧索硬化症 (ALS)、阿尔茨海默病和帕金森病，这些疾病代表着巨大的市场机遇和大量未满足的需求。虽然这些结果仍处于临床前阶段，但其针对衰老基本过程而非仅仅针对症状的机制方法展现了其科学的复杂性。多器官获益表明，其应用范围不仅局限于神经退行性疾病，还可能扩展到更广泛的抗衰老治疗领域——这是一个快速增长的细分市场。参考资料：[1]https://www.prnewswire.com/news-releases/klotho-neuroscience-inc-announces-an-approach-to-increase-longevity-and-healthy-life-span--replace-a-silenced-gene-called-alpha-klotho--klotho-302476036.html[2]Roig-Soriano J, Edo Á, Verdés S, et al. Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience. Mol Ther. 2025;33(4):1449-1465. doi:10.1016/j.ymthe.2025.02.030","news_type":1,"symbols_score_info":{"KLTO":0.9}},"isVote":1,"tweetType":1,"viewCount":823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":445091186847848,"gmtCreate":1749686371755,"gmtModify":1749691844357,"author":{"id":"49788700068555","authorId":"49788700068555","name":"九哥","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"49788700068555","authorIdStr":"49788700068555"},"themes":[],"htmlText":"在美股中上市的稀土相关股票，以及各自的市场竞争优势","listText":"在美股中上市的稀土相关股票，以及各自的市场竞争优势","text":"在美股中上市的稀土相关股票，以及各自的市场竞争优势","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/445091186847848","repostId":"2542320144","repostType":2,"isVote":1,"tweetType":1,"viewCount":823,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}